Macro Group Pharmaceuticals - Macro Capital S.A.E results, Q4 2024
Net profit, assets, equity and cash flow for Q4 2024, against the same period a year earlier, from the published financial statements.
Net profit-38.1 millionEGP · +86.0% vs the same period a year earlier
Total assets615 millionEGP · +19.7% vs the same period a year earlier
Shareholders' equity78.1 millionEGP · −17.2% vs the same period a year earlier
Operating cash flow-74.45 millionEGP · −95.9% vs the same period a year earlier
In short
- Macro Group Pharmaceuticals - Macro Capital S.A.E's net profit for Q4 2024 was about -38.1 million EGP, up +86.0% from -273 million EGP in Q4 2023.
- Total assets at the end of Q4 2024 were about 615 million EGP, and shareholders' equity about 78.1 million EGP.
- Operating cash flow for Q4 2024 was negative at 74.45 million EGP.
Key lines against the same period a year earlier
This periodQ4 2023Change
Net profit-38.1 million-273 million+86.0%
Gross profit340 million313 million+8.7%
Total assets615 million514 million+19.7%
Total liabilities537 million419 million+28.0%
Shareholders' equity78.1 million94.33 million−17.2%
Total liabilities and equity615 million514 million+19.7%
Operating cash flow-74.45 million-38.01 million−95.9%
Investing cash flow18.56 million-4.42 million+520.2%
Financing cash flow42.92 million-69.02 million+162.2%
Net change in cash-12.97 million46.33 million−128.0%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Macro Group Pharmaceuticals - Macro Capital S.A.E's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy